Investigator

Jürgen Grünberg

Senior Research Scientist · Paul Scherrer Institut, Center for Radiopharmaceutical Sciences

JGJürgen Grünberg
Papers(1)
Phosphoproteomics Rev…
Collaborators(5)
Martin BéhéMichal GrzmilRoger SchibliTihomir Zh TodorovFrancis Jacob
Institutions(3)
Unknown InstitutionETH ZurichUniversity Of Basel

Papers

Phosphoproteomics Reveals L1CAM-Associated Signaling Networks in High-Grade Serous Ovarian Carcinoma: Implications for Radioresistance and Tumorigenesis

Quantitative phosphoproteomics enables the comprehensive analysis of signaling pathways driven by overexpressed cancer receptors, revealing the molecular mechanisms that underpin tumor progression and therapy resistance. The glycoprotein L1 cell adhesion molecule (L1CAM) is overexpressed in high-grade serous ovarian carcinoma (HGSOC) and plays a crucial role in carcinogenesis by regulating cancer stem cell properties. Here, CRISPR–Cas9-mediated knockout of L1CAM in ovarian cancer OVCAR8 and OVCAR4 cells significantly impaired anchor-independent growth in soft agar assays and reduced clonogenic survival following external beam irradiation. In vivo, L1CAM knockout decreased cancer stem cell frequency and significantly decreased tumorigenicity. To uncover L1CAM-regulated signaling networks, we employed quantitative phosphoproteomics and proteomics. Bioinformatics analyses and validation studies revealed L1CAM-associated pathways that contribute to radioresistance through DNA repair processes and mammalian target or rapamycin complex 1 (mTORC1)-mediated signaling. In conclusion, our study established a link between L1CAM-dependent tumorigenesis and radioresistance, both hallmarks of cancer stemness, with phosphorylation of key proteins involved in DNA damage response. This study further emphasizes the value of quantitative phosphoproteomics in cancer research, showcasing its ability to enhance understanding of cancer progression and therapy resistance.

3Works
1Papers
5Collaborators
Ovarian NeoplasmsCell Line, TumorCystadenocarcinoma, Serous

Positions

2001–

Senior Research Scientist

Paul Scherrer Institut · Center for Radiopharmaceutical Sciences